Vinblastine adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Vinblastine
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Product name as reported
Also reported as: Vinblastine /00115802/

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From February 2004 to June 2026, FDA received 4,765 adverse event reports that name Vinblastine. The name is as reporters wrote it. In these reports the drug is a suspect or interacting product.

In the same period, 924 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 314 reports in the 12 months to June 2026 and 457 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 314 (under 0.1%) name Vinblastine. Reports from consumers or other non-health professionals were 4.4% of the reports that name Vinblastine and 45.8% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Vinblastine is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 75 reports that name Vinblastine.
In January to March 2026, FDA received 97.
In April to June 2025, FDA received 70.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 420 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 4,737 of the 4,765 reports (99.4%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 420 terms.

Reaction terms in the reports that name Vinblastine, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 4,765 reports
Off label useused for a purpose or in a way not on the label	465	9.8%
Febrile neutropeniafever with low white blood cells	422	8.9%
Neutropenialow neutrophils, a type of white blood cell	350	7.3%
Drug ineffectivethe medicine did not work as expected	308	6.5%
Disease progressionthe disease advanced	235	4.9%
Product use in unapproved indicationused for a purpose not on the label	234	4.9%
Neuropathy peripheralnerve damage in hands or feet	220	4.6%
Pyrexiafever	194	4.1%
Nauseafeeling sick	171	3.6%
Vomitingbeing sick	161	3.4%
Second primary malignancy	155	3.3%
Sepsisa severe body-wide response to infection	153	3.2%
Malignant neoplasm progression	151	3.2%
Thrombocytopenialow platelets	143	3%
Hodgkin's disease	139	2.9%
Acute myeloid leukaemia	137	2.9%
Diarrhoealoose or frequent stools	136	2.9%
Respiratory failurethe lungs could not supply enough oxygen	135	2.8%
Pneumonialung infection	130	2.7%
Anaemialow red blood cells	127	2.7%
Pancytopenialow counts of all blood cells	126	2.6%
Deaththe patient died; cause not stated by this term	122	2.6%
Fatiguetiredness	120	2.5%
Toxicity to various agentspoisoning or toxic effect of one or more substances	98	2.1%
Treatment failurethe treatment did not work	91	1.9%
Pulmonary toxicity	90	1.9%
Abdominal painstomach or belly pain	89	1.9%
Constipation	84	1.8%
Infectionan infection, type not specified	84	1.8%
Disease recurrencethe disease came back	78	1.6%
Dyspnoeashortness of breath	78	1.6%
Foetal exposure during pregnancythe unborn baby was exposed to the medicine	75	1.6%
Mucosal inflammation	75	1.6%
Lung disordera lung problem, type not specified	71	1.5%
Drug intolerancethe medicine was not tolerated	68	1.4%
Myelodysplastic syndrome	67	1.4%
Exposure during pregnancythe medicine was taken during pregnancy	66	1.4%
Headachehead pain	66	1.4%
Neoplasm progression	66	1.4%
Haematotoxicity	65	1.4%
Painpain, site not specified	63	1.3%
Product use issuea problem in how the product was used	63	1.3%
Bone marrow failure	62	1.3%
Tachycardiafast heart rate	60	1.3%
Decreased appetitereduced appetite	59	1.2%
Cough	57	1.2%
Premature babya baby born early	56	1.2%
Lymphadenopathyswollen lymph nodes	55	1.2%
Pneumonitis	55	1.2%
Septic shockshock arising from infection	55	1.2%

Download all 420 terms of Vinblastine (CSV)

The counts add to more than 4,765 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Vinblastine, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	10	3	0	0	1	0	0	3	7
2005	37	28	3	0	15	0	0	16	9
2006	13	13	3	1	7	0	0	6	0
2007	4	4	2	1	2	0	0	2	0
2008	2	2	0	0	0	0	0	2	0
2009	40	40	8	1	12	0	0	25	0
2010	15	15	2	0	8	0	0	10	0
2011	44	44	11	1	7	0	0	29	0
2012	86	85	28	1	17	1	3	56	1
2013	113	113	25	2	37	2	0	69	0
2014	129	128	28	1	34	1	0	88	1
2015	234	221	58	7	77	4	0	144	13
2016	271	267	60	10	84	4	0	187	4
2017	316	312	111	30	50	3	3	243	4
2018	442	422	64	14	89	10	4	342	20
2019	427	410	107	34	115	6	8	288	17
2020	447	431	83	31	134	11	5	341	16
2021	363	335	94	43	114	2	0	240	28
2022	360	325	65	18	82	3	0	266	35
2023	412	396	82	50	109	15	0	322	16
2024	502	459	74	26	145	8	1	383	43
2025	297	289	47	29	76	4	4	252	8
2026	201	200	62	51	53	2	0	160	1

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Vinblastine, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Vinblastine, by the year in which FDA received them
Year	Reports
2004	6
2005	41
2006	13
2007	5
2008	2
2009	40
2010	15
2011	46
2012	107
2013	119
2014	126
2015	255
2016	263
2017	362
2018	469
2019	457
2020	482
2021	329
2022	320
2023	392
2024	481
2025	263
2026	172

Reports that name Vinblastine, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Vinblastine
Age	Reports	Share
Under 2	131	2.7%
2 to 11	245	5.1%
12 to 17	168	3.5%
18 to 44	1,212	25.4%
45 to 64	660	13.9%
65 to 74	348	7.3%
75 and over	147	3.1%
Age not given	1,854	38.9%

Sex of the patient in the reports that name Vinblastine
Sex	Reports	Share
Female	1,532	32.2%
Male	1,800	37.8%
Unknown or not given	1,433	30.1%

Type of reporter in the reports that name Vinblastine
Reporter	Reports	Share
Physician	1,993	41.8%
Pharmacist	119	2.5%
Other health professional	2,345	49.2%
Lawyer	1	under 0.1%
Consumer or non-health professional	211	4.4%
Not given	96	2%

Age and sex are as the report gives them. The reporter is the primary source in the report. 39.1% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Vinblastine record
Indication as recorded (MedDRA)	Reports	Share
Hodgkin's disease	2,368	49.7%
Langerhans' cell histiocytosis	142	3%
Hodgkin's disease	75	1.6%
Bladder cancer	68	1.4%
Transitional cell carcinoma	67	1.4%
Chemotherapy	53	1.1%

The reporter fills in the indication, and the field is often empty. Each share is of all 4,765 reports.

Drugs in the same reports

Other drugs that the reports of Vinblastine name, in any role, in order of name
Drug	Reports that name the two
Adcetris	626
Bleomycin	1,938
Cisplatin	807
Cyclophosphamide	890
Dacarbazine	3,031
Doxorubicin	2,097
Doxorubicin hydrochloride	990
Etoposide	1,021
Prednisone	808
Vincristine	748

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Vimpat next in the A to Z list
Vinblastine sulfate next in the A to Z list
Vimovo next in the A to Z list
Vincristin next in the A to Z list
Vimizim next in the A to Z list
Vincristine next in the A to Z list
Vildagliptin next in the A to Z list
Vincristine Hospira next in the A to Z list
Vilazodone next in the A to Z list
Vincristine sulfate next in the A to Z list
Vilanterol trifenatate next in the A to Z list
Vincristine sulphate next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for VinblastineThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Vinblastine: adverse event reports that FDA received. https://reportedreactions.com/drug/vinblastine/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Vinblastine as a suspect or interacting product. The 924 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Vinblastine was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Vinblastine?

No. It is a count of what people reported to FDA: 4,765 reports from February 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (49.2%), physician (41.8%) and consumer or non-health professional (4.4%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page